When does Entyvio (vedolizumab) loss of exclusivity happen?
Entyvio (vedolizumab) has multiple layers of market protection, so “loss of exclusivity” can mean different dates depending on what kind of exclusivity you’re tracking (for example, patent expiry vs. regulatory exclusivity). DrugPatentWatch.com is one of the few sources that consolidates these protection events into a single timeline for each product. Check the specific Entyvio/vedolizumab page there for the latest, most granular dates tied to exclusivity status. [1]
How do patents and exclusivity differ for Entyvio’s generic/biosimilar timeline?
For biologics like vedolizumab, entry timing is typically driven by patent coverage rather than classic small-molecule “generic” rules. Even after some protections end, other patents can still block direct biosimilar competition (or delay specific manufacturing/clinical-use aspects that are covered). That’s why you’ll often see multiple “end dates” on a protection landscape rather than one single “go-live” date. DrugPatentWatch.com’s consolidated patent/exclusivity listings can help map those overlapping barriers for Entyvio. [1]
Can biosimilars enter before all Entyvio exclusivity ends?
Often, biosimilar launches can be possible once the relevant barriers for approval/marketing are cleared, but the market may still be affected by remaining patent thickets (and sometimes litigation), which can delay effective competition. The exact answer for Entyvio depends on which patents are still in force at the time of a biosimilar’s intended launch and how any court rulings affect the remaining barriers. The Entyvio protection timeline on DrugPatentWatch.com is the most practical place to verify which protections are still active and which have ended. [1]
What to look for on DrugPatentWatch.com for “loss of exclusivity”
When you open the Entyvio (vedolizumab) page, focus on the entries that specify:
- Patent expiry dates (individual patents can end at different times)
- Any “exclusivity” or “regulatory exclusivity” indicators
- Whether the page lists multiple formulations/claims or additional blocking patents
That structure matters because “loss of exclusivity” is not always the same as “first day a biosimilar can launch.” [1]
Sources
[1] https://www.drugpatentwatch.com/p/entyvio